About Us
pipeline
-
AM-928 (Anti-EpCAM mAb)
Epithelial cell adhesion molecule (EpCAM) is a highly expressed antigen in various solid tumors including, colorectal, gastric, head and neck and ovarian cancers, which holds a critical position in tumor progression process.
-
SB-001 (Anti-COVID-19 mAb)
AcadeMab has discovered a panel of fully human monoclonal antibodies (mAbs) directly against receptor binding domain (RBD) of SARS-CoV-2 spike (Spike) protein from SARS-CoV-2 vaccine recipients by human single B cell technology.
-
AM-168 (Anti-HER3 mAb)
Human epidermal growth factor receptor 3 (HER3), a membrane-bound receptor tyrosine kinase disrupted in multiple cancers, including breast, lung and colorectal cancers, among others.
-
AM-DV-01 (Dengue mRNA vaccine)
AM-DV-01 is an advanced mRNA vaccine used to prevent severe dengue fever.
News
-
-
2024/11/12研生登革熱mRNA疫苗+新型陽離子脂質獲莫德納前瞻新創獎
第二屆「2024莫德納台灣mRNA前膽新創獎」於11月8日公布獲獎名單，中研院衍生新創公司研生生醫，成功將核酸技術與創新陽離子脂質結合，以脂質奈米粒（LNP）傳輸平台開發出「安全暨有效的登革熱核酸疫苗」，從35組團隊中脫穎而出。
more -
2024/05/30研生生醫榮獲NBRP Demo Day潛力新秀獎及國際市場獎，兩項大獎加冕
研生生醫在2024年NBRP Demo Day上憑藉抗體新藥AM-928及核心技術，獲得潛力新秀獎和國際市場獎。活動吸引500多位業界人士，研生生醫的成功展示了其全球市場潛力。
more -
2023/09/14AcadeMab announced the initiation of Phase 1 clinical trial of an anti-EpCAM monoclonal antibody, AM-928 for treatment of patients with advanced solid tumors
The first subject of this trail has enrolled, and a total of 30 subjects are expected to participate in this clinical trial
more -
2023/09/14AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids
AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term.
more -
2023/09/13研生生醫3年抗體新藥進IND 再引mRNA疫苗技術雙引擎發展
研⽣精準醫療抗體新藥AM-928 於年初取得美國IND後，並進一步自中研院引進mRNA疫苗平台成為研生的另一顆引擎。
more -
2023/03/06研生精準醫療抗體新藥AM-928取得美國IND 對多種癌症治療具臨床潛力
研⽣精準醫療抗體新藥AM-928 取得美國IND
more
對多種癌症治療具臨床潛⼒ 將展開一期臨床試驗 -
2022/06/22AcadeMab makes its mark at 2022 BIO USA
Visitors to the 2022 BIO International Convention in San Diego check out at booth of AcadeMab Biomedical Inc. at the Taiwan Pavilionto market the products and seek new business opportunities.
more
technology
-
Human single B cell antibody technology
Human single B cell antibody technology is an attractive and efficient approach to discovery human monoclonal antibody from vaccine recipients or convalescent patients. The standard process included the screening of antigen-specific memory B cells, the amplification of variable region, the construction of expression vector, the production and characterization of mAbs.
-
Phage display
Phage display is a technology to insert the DNA sequence of foreign protein or peptide into the appropriate position of phage coat protein structural gene, so the exogenous gene can be expressed and shown on the surface of phage. By using this technology, a phage library can be established to express a wide diversity of peptides or proteins and can be used to select those binding to the desired targets.
-
Human antibody mouse
AcadeMab’s antibody mouse is to replace the original mouse antibody genes by human antibody genes.
-
AM-D001 (Anti-M13 antibody)
Human single B cell antibody technology is an attractive and efficient approach to discovery human monoclonal antibody from vaccine recipients or convalescent patients.
